Linden Advisors’s Aspire Biopharma Warrant ASBPW Stock Holding History

Linden Advisors’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21K	Hold	899,999	–	–	﹤0.01%	614
2026 Q1	$16.9K	Hold	899,999	–	–	﹤0.01%	540
2025 Q4	$17.7K	Hold	899,999	–	–	﹤0.01%	456
2025 Q3	$25.2K	Hold	899,999	–	–	﹤0.01%	386
2025 Q2	$40.5K	Hold	899,999	–	–	﹤0.01%	346
2025 Q1	$65.7K	Hold	899,999	–	–	﹤0.01%	258
2024 Q4	$36.2K	Hold	899,999	–	–	﹤0.01%	225
2024 Q3	$34K	Hold	899,999	–	–	﹤0.01%	209
2024 Q2	$32.6K	Hold	899,999	–	–	﹤0.01%	225
2024 Q1	$30.5K	Hold	899,999	–	–	﹤0.01%	251
2023 Q4	$58.5K	Hold	899,999	–	–	﹤0.01%	226
2023 Q3	$44.6K	Hold	899,999	–	–	﹤0.01%	266
2023 Q2	$49.5K	Hold	899,999	–	–	﹤0.01%	266
2023 Q1	$40.5K	Hold	899,999	–	–	﹤0.01%	335
2022 Q4	$36.6K	Hold	899,999	–	–	﹤0.01%	428
2022 Q3	$131K	Hold	899,999	–	–	﹤0.01%	478
2022 Q2	$144K	Buy	+899,999	New	+$196K	﹤0.01%	510

Other funds holding ASBPW

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Linden Advisors's ASBPW Position: Q2 2026 in Review

Linden Advisors held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 899,999 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #614.

Linden Advisors first reported a position in ASBPW in Q2 2022 and has held it in 17 quarters since. The position peaked at $144K in Q2 2022. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

Linden Advisors held 899,999 shares of Aspire Biopharma Warrant worth $21K as of Q2 2026.
Linden Advisors left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
Aspire Biopharma Warrant made up ﹤0.01% of Linden Advisors's portfolio in Q2 2026, its #614 holding.
Linden Advisors first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 17 quarters since.
Linden Advisors's Aspire Biopharma Warrant position peaked at $144K in Q2 2022.
27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Linden Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.